You’re making all the
difference
Thanks to the incredible generosity of our donors and our community alongside BCNA’s unwavering advocacy, access to Enhertu was expanded to include people with HER2-low metastatic breast cancer. It was recomended for listing following BCNA’s call for action by the Federal Minister for Health. This significant achievement underscores BCNA’s dedication to ensuring equitable access to care and treatment for all Australians affected by breast cancer. Each year, around 1,700 people are expected to benefit from this listing — people who, without subsidy, might face costs exceeding $200,000. Now, eligible patients will pay no more than $31.60 per script or just $7.70 with a concession card. This means Australians who need this life-prolonging medication will now save approximately $12,500 every three weeks! Only with your continued support can BCNA help ensure that people like Sarah can access the breast cancer treatments they need — without the added financial burden.
Time with my family that I didn’t think I’d have. Time for hope for further medical advancements. Time to advocate for myself and others. Time to run marathons and live life to the fullest. I still have cancer, but I’m thriving. – Sarah
OUR 2023-24 IMPACT AT A GLANCE
13,558 calls and emails to the Helpline
199,890 visits to BCNA online network communities
88,955 BCNA podcast listeners
Seven
529,987
15,893 My Care Kits distributed
PBS submissions made in support of subsidised drugs, devices, and tests
website visitors accessing our information and resources
03
Made with FlippingBook - professional solution for displaying marketing and sales documents online